121490-67-3

Basic information

• Product Name: 8-BROMOQUINOLINE-4-CARBOXYLIC ACID
• Synonyms: 8-BROMOQUINOLINE-4-CARBOXYLIC ACID;8-bromo-4-Quinolinecarboxylic acid
• CAS NO: 121490-67-3
• Molecular Formula: C10H6BrNO2
• Molecular Weight: 252.06414
• Mol File: 121490-67-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 403.1 °C at 760 mmHg
• Flash Point: 197.6 °C
• Appearance: /
• Density: 1.732 g/cm³
• Vapor Pressure: 3.21E-07mmHg at 25°C
• Refractive Index: 1.709
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 2.83±0.30(Predicted)
• CAS DataBase Reference: 8-BROMOQUINOLINE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BROMOQUINOLINE-4-CARBOXYLIC ACID(121490-67-3)
• EPA Substance Registry System: 8-BROMOQUINOLINE-4-CARBOXYLIC ACID(121490-67-3)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 121490-67-3(Hazardous Substances Data)

Usage

Uses

8-BROMOQUINOLINE-4-CARBOXYLIC ACID is a useful research chemical.

InChI:InChI=1/C10H6BrNO2/c11-8-3-1-2-6-7(10(13)14)4-5-12-9(6)8/h1-5H,(H,13,14)

Upstream product

• 20780-74-9 7-bromoisatin 
• 172939-50-3 8-bromo-4-methylquinoline 
• 898391-87-2 8-bromo-quinoline-4-carbaldehyde 
• 615-36-1 2-bromoaniline 

Downstream Products

• 1476076-33-1 8-bromo-N-methyl-quinoline-4-carboxamide 
• 1476074-39-1 (S)-N-methyl-8-(1-((2'-methyl-4',6'-dideutero-[4,5'-bipyrimidin]-6-yl)amino)propan-2-yl)quinoline-4-carboxamide 

Relevant articles and documents

Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold

Fibroblast activation protein (FAP) is a serine protease that is generally accepted to play an important role in tumor growth and other diseases involving tissue remodeling. Currently there are no FAP inhibitors with reported selectivity toward both the closely related dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP). We present the discovery of a new class of FAP inhibitors with a N-(4-quinolinoyl)-Gly-(2-cyanopyrrolidine) scaffold. We have explored the effects of substituting the quinoline ring and varying the position of its sp2 hybridized nitrogen atom. The most promising inhibitors combined low nanomolar FAP inhibition and high selectivity indices (>10 3) with respect to both the DPPs and PREP. Preliminary experiments on a representative inhibitor demonstrate that plasma stability, kinetic solubility, and log D of this class of compounds can be expected to be satisfactory.

CO-CRYSTALS OF (S)-N-METHYL-8-(1-((2'-METHYL-[4,5'-BIPYRIMIDIN]-6-YL)AMINO)PROPAN-2-YL)QUINOLINE-4-CARBOXAMIDE AND DEUTERATED DERIVATIVES THEREOF AS DNA-PK INHIBITORS

The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.

NOVEL FAP INHIBITORS

The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.